Jcr Pharmaceuticals Co. Ltd.
- Address
- 3-19 Kasugacho
Sponsor Overview
Specializations
Hunter syndrome and mucopolysaccharidosis type II
JCR Pharmaceuticals Co. Ltd. focuses on clinical research in Hunter syndrome, with particular attention to mucopolysaccharidosis type II and its impact on both central nervous system and somatic symptoms.
- Central nervous system involvement
- Somatic disease manifestations
- Long-term symptom control
The sponsor’s trial activity in this area also includes assessment of safety and pharmacokinetics in patients with MPS II.
Mucopolysaccharidosis type IIIA
Clinical research also extends to mucopolysaccharidosis type IIIA (MPS IIIA), a rare lysosomal storage disorder associated with progressive neurological involvement.
- Neurological disease burden
- Safety evaluation
- Exploratory efficacy assessment
This area reflects interest in therapies directed at the neurologic manifestations of inherited metabolic disease.
Rare disease therapeutics
The sponsor’s trial portfolio is concentrated in rare genetic disorders affecting glycosaminoglycan metabolism, with a clear therapeutic emphasis on mucopolysaccharidoses.
- Inherited metabolic disease
- Enzyme-related pathology
- Neurometabolic treatment targets
Its research landscape is centered on conditions with both systemic and neurological disease components.
Neurology-linked metabolic disorders
JCR Pharmaceuticals Co. Ltd. shows a strong therapeutic interest in disorders where neurologic impairment coexists with multisystem involvement, especially in pediatric and inherited disease settings.
- Neurocognitive symptoms
- Multisystem disease expression
- Rare pediatric disorders
This focus positions the sponsor within the field of orphan disease research, particularly for conditions with unmet neurological treatment needs.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety and Efficacy of JR-441 in Mucopolysaccharidosis Type IIIA via Weekly Intravenous Infusions |  Germany | Not Recruiting |
| Long-term Safety and Efficacy Evaluation of Pabinafusp Alfa in Patients with Mucopolysaccharidosis Type II (Hunter Syndrome) |  France Germany Italy Poland Spain | Recruiting |
| Phase III Evaluation of Pabinafusp Alfa and Idursulfase in Patients with Mucopolysaccharidosis Type II (Hunter Syndrome) | France Germany Italy Poland Spain | Not Recruiting |
Data & Insights
This sponsor works with 3 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 16 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities3 trials165 other sponsors
Partnered Research Centres
16 centres- Address
- 26 Avenue Du Docteur Arnold Netter, 75012 Paris
- Address
- Langenbeckstrasse 1, Oberstadt, 55131 Mainz
- Address
- 165 Chemin Du Grand Revoyet, 69310 Pierre Benite
- Address
- 80 Avenue Augustin Fliche, 34295 Montpellier
- Address
- Via Giovanbattista Pergolesi 33, 20900 Monza
- Address
- 52 Boulevard Pinel, 69500 Bron
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Jcr Pharmaceuticals Co. Ltd..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.